Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)

Natasha Kekre; Haesook T. Kim; Julia Hofer; Vincent T. Ho; John Koreth; Philippe Armand; Sarah Nikiforow; Mahasweta Gooptu; Rizwan Romee; Edwin P. Alyea; Prashant Nageshwar; Brett Glotzbecker; Areej El-Jawahri; Zachariah DeFilipp; Robert J. Soiffer; Joseph H. Antin; Yi Bin Chen; Corey Cutler

doi:10.1038/s41409-020-01083-y

Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)

Natasha Kekre, Haesook T. Kim, Julia Hofer, Vincent T. Ho, John Koreth, Philippe Armand, Sarah Nikiforow, Mahasweta Gooptu, Rizwan Romee, Edwin P. Alyea, Prashant Nageshwar, Brett Glotzbecker, Areej El-Jawahri, Zachariah DeFilipp, Robert J. Soiffer, Joseph H. Antin, Yi Bin Chen, Corey Cutler

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

The original version of the Article stated in the Methods section that Natalizumab was provided by Genentech. In fact, it was provided by Biogen. This has now been corrected in both the PDF and HTML versions of the Article.

Original language	English (US)
Pages (from-to)	1217
Number of pages	1
Journal	Bone marrow transplantation
Volume	56
Issue number	5
DOIs	https://doi.org/10.1038/s41409-020-01083-y
State	Published - May 2021
Externally published	Yes

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/s41409-020-01083-y

Fingerprint

Dive into the research topics of 'Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)'. Together they form a unique fingerprint.

Cite this

Kekre, N., Kim, H. T., Hofer, J., Ho, V. T., Koreth, J., Armand, P., Nikiforow, S., Gooptu, M., Romee, R., Alyea, E. P., Nageshwar, P., Glotzbecker, B., El-Jawahri, A., DeFilipp, Z., Soiffer, R. J., Antin, J. H., Chen, Y. B., & Cutler, C. (2021). Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0). Bone marrow transplantation, 56(5), 1217. https://doi.org/10.1038/s41409-020-01083-y

Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0). / Kekre, Natasha; Kim, Haesook T.; Hofer, Julia et al.
In: Bone marrow transplantation, Vol. 56, No. 5, 05.2021, p. 1217.

Research output: Contribution to journal › Comment/debate › peer-review

Kekre, N, Kim, HT, Hofer, J, Ho, VT, Koreth, J, Armand, P, Nikiforow, S, Gooptu, M, Romee, R, Alyea, EP, Nageshwar, P, Glotzbecker, B, El-Jawahri, A, DeFilipp, Z, Soiffer, RJ, Antin, JH, Chen, YB & Cutler, C 2021, 'Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)', Bone marrow transplantation, vol. 56, no. 5, pp. 1217. https://doi.org/10.1038/s41409-020-01083-y

@article{07738dcb512f429893272915e833378c,

title = "Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)",

abstract = "The original version of the Article stated in the Methods section that Natalizumab was provided by Genentech. In fact, it was provided by Biogen. This has now been corrected in both the PDF and HTML versions of the Article.",

author = "Natasha Kekre and Kim, {Haesook T.} and Julia Hofer and Ho, {Vincent T.} and John Koreth and Philippe Armand and Sarah Nikiforow and Mahasweta Gooptu and Rizwan Romee and Alyea, {Edwin P.} and Prashant Nageshwar and Brett Glotzbecker and Areej El-Jawahri and Zachariah DeFilipp and Soiffer, {Robert J.} and Antin, {Joseph H.} and Chen, {Yi Bin} and Corey Cutler",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2021",

month = may,

doi = "10.1038/s41409-020-01083-y",

language = "English (US)",

volume = "56",

pages = "1217",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Correction

T2 - Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)

AU - Kekre, Natasha

AU - Kim, Haesook T.

AU - Hofer, Julia

AU - Ho, Vincent T.

AU - Koreth, John

AU - Armand, Philippe

AU - Nikiforow, Sarah

AU - Gooptu, Mahasweta

AU - Romee, Rizwan

AU - Alyea, Edwin P.

AU - Nageshwar, Prashant

AU - Glotzbecker, Brett

AU - El-Jawahri, Areej

AU - DeFilipp, Zachariah

AU - Soiffer, Robert J.

AU - Antin, Joseph H.

AU - Chen, Yi Bin

AU - Cutler, Corey

PY - 2021/5

Y1 - 2021/5

N2 - The original version of the Article stated in the Methods section that Natalizumab was provided by Genentech. In fact, it was provided by Biogen. This has now been corrected in both the PDF and HTML versions of the Article.

AB - The original version of the Article stated in the Methods section that Natalizumab was provided by Genentech. In fact, it was provided by Biogen. This has now been corrected in both the PDF and HTML versions of the Article.

UR - http://www.scopus.com/inward/record.url?scp=85092351448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092351448&partnerID=8YFLogxK

U2 - 10.1038/s41409-020-01083-y

DO - 10.1038/s41409-020-01083-y

M3 - Comment/debate

C2 - 33041331

AN - SCOPUS:85092351448

SN - 0268-3369

VL - 56

SP - 1217

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 5

ER -

Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease (Bone Marrow Transplantation, (2021), 56, 5, (1006-1012), 10.1038/s41409-020-01049-0)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this